Pharsight

Uceris patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9192581 SALIX Controlled release and taste masking oral pharmaceutical composition
Sep, 2031

(7 years from now)

US8895064 SALIX Controlled release and taste masking oral pharmaceutical composition
Sep, 2031

(7 years from now)

US10660858 SALIX Controlled release and taste masking oral pharmaceutical composition
Sep, 2031

(7 years from now)

US9132093 SALIX Controlled release and taste making oral pharmaceutical composition
Sep, 2031

(7 years from now)

US10307375 SALIX Controlled release and taste masking oral pharmaceutical composition
Sep, 2031

(7 years from now)

Uceris is owned by Salix.

Uceris contains Budesonide.

Uceris has a total of 5 drug patents out of which 0 drug patents have expired.

Uceris was authorised for market use on 14 January, 2013.

Uceris is available in tablet, extended release;oral dosage forms.

Uceris can be used as induction of remission in patients with active, mild to moderate ulcerative colitis.

The generics of Uceris are possible to be released after 07 September, 2031.

Drugs and Companies using BUDESONIDE ingredient

Market Authorisation Date: 14 January, 2013

Treatment: Induction of remission in patients with active, mild to moderate ulcerative colitis

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of UCERIS before it's drug patent expiration?
More Information on Dosage

UCERIS family patents

Family Patents